|
gptkbp:instanceOf
|
gptkb:receptor_tyrosine_kinase
gptkb:drug
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:approvalYear
|
2013
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L01EB03
|
|
gptkbp:bioavailability
|
92%
|
|
gptkbp:brand
|
gptkb:Gilotrif
gptkb:Giotrif
|
|
gptkbp:CASNumber
|
439081-18-2
|
|
gptkbp:category
|
protease inhibitor
antineoplastic agent
quinazoline derivative
|
|
gptkbp:contraindication
|
hypersensitivity to afatinib
|
|
gptkbp:developedBy
|
gptkb:Boehringer_Ingelheim
|
|
gptkbp:discoveredBy
|
gptkb:Boehringer_Ingelheim
|
|
gptkbp:eliminationHalfLife
|
37 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C24H25ClFN5O3
|
|
gptkbp:hasSMILES
|
COC1=CC2=C(C=C1)N=C(NC3=CC=C(C=C3)F)N2CC4=CC=C(C=C4)Cl
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Afatinib
|
|
gptkbp:interactsWith
|
P-glycoprotein inducers
P-glycoprotein inhibitors
|
|
gptkbp:KEGGID
|
D09722
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
irreversible inhibitor of EGFR and HER2
|
|
gptkbp:metabolism
|
minimal hepatic metabolism
|
|
gptkbp:patentExpired
|
2024 (US)
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:pregnancyWarning
|
may cause fetal harm
|
|
gptkbp:proteinBinding
|
95%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1173655
gptkb:DB08916
10184653
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
diarrhea
rash
stomatitis
paronychia
|
|
gptkbp:synonym
|
gptkb:BIBW_2992
|
|
gptkbp:target
|
gptkb:EGFR
HER2
|
|
gptkbp:UNII
|
J2U8A8C830
|
|
gptkbp:usedFor
|
gptkb:non-small_cell_lung_cancer
metastatic lung cancer
|
|
gptkbp:bfsParent
|
gptkb:Non-Small_Cell_Lung_Cancer
|
|
gptkbp:bfsLayer
|
6
|